CCT365623 hydrochloride

Name: CCT365623 hydrochloride
Brand: MedChemExpress
SKU: HY-124674A
Rating: 4.5 (1 reviews)

Cat. No.: HY-124674A Purity: 98.07%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

CCT365623 hydrochloride is an orally active lysyl oxidase (LOX) inhibitor, with an IC₅₀ of 0.89 μM. CCT365623 hydrochloride suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF. CCT365623 hydrochloride is extremely well tolerated, and has good pharmacokinetic properties.

For research use only. We do not sell to patients.

CCT365623 hydrochloride Chemical Structure

CAS No. : 2126136-98-7

Size	Price	Stock	Quantity
5 mg	USD 400	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 640	In-stock	Estimated Time of Arrival: December 31
25 mg	USD 1350	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 2150	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 3350	In-stock	Estimated Time of Arrival: December 31
200 mg		Get quote
500 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of CCT365623 hydrochloride:

CCT365623 Get quote

1 Publications Citing Use of MCE CCT365623 hydrochloride

•Cell Chem Biol. 2024 Jul 9:S2451-9456(24)00273-3. [Abstract]

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Monoamine Oxidase Isoform Specific Products:

View All Isoforms

MAO-A MAO-B

View All EGFR Isoform Specific Products:

View All Isoforms

EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

View All Akt Isoform Specific Products:

View All Isoforms

Akt Akt1 Akt2 Akt3

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

IC50: 0.89 μM (LOX)^[1].

In Vitro

CCT365623 inhibits LOX at ~5 μM in the biosensor system^[1].
CCT365623 (0-40 μM) concentration-dependently decreases the protein levels of surface EGFR^[1].
CCT365623 (5 μM) decreases the protein levels of pY1068 EGFR, pAKT and MATN2, and increases the protein levels of pSMAD2^[1].
CCT365623 disrupts HTRA1 multimerization, activates TGFβ1 signalling, suppresses MATN2 expression, suppresses EGFR surface retention, and suppresses EGFR signalling^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:	MDA-MB-231 cells.
Concentration:	0-40 μM.
Incubation Time:	24 hours
Result:	Significantly decreased the protein levels of surface EGFR, pY1068 EGFR, pAKT and MATN2. Increased the protein levels of pSMAD2.

In Vivo

CCT365623 displays good stability in mouse liver microsomes and does not inhibit the cardiac potassium channel hERG^[1].
CCT365623 (70 mg/kg, oral gavage per day) significantly delays the development of the primary tumors and also suppresses metastatic lung burden in the animals. CCT365623 disrupts EGFR cell surface retention and delays the growth of primary and metastatic tumor cell^[1].
CCT365623 exhibits a T_1/2PO of 0.6 h and F% (oral bioavailability) of 45%^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mouse model of spontaneous breast cancer that metastasizes to the lungs (70 days old)^[1].
Dosage:	70 mg/kg.
Administration:	Oral gavage per day for about 3 weeks.
Result:	Significantly reduced MATN2 protein levels in both the primary and metastatic lung tumors and this is accompanied by the loss of EGFR from the plasma membranes of the cells in both the primary and metastatic tumors.

Molecular Weight

443.99

Formula

C₁₈H₁₈ClNO₄S₃

CAS No.

2126136-98-7

Appearance

Solid

Color

White to yellow

SMILES

NCC1=CC=C(S(=O)(C2=CC(C3=CC=CC=C3)=CC(S(=O)(C)=O)=C2)=O)S1.Cl

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 250 mg/mL (563.08 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.2523 mL	11.2615 mL	22.5230 mL
5 mM	0.4505 mL	2.2523 mL	4.5046 mL
10 mM	0.2252 mL	1.1262 mL	2.2523 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (4.68 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 98.07%

Select Batch:

Data Sheet (277 KB) SDS (252 KB)

COA (252 KB) HNMR (268 KB) RP-HPLC (261 KB)

Handling Instructions (2659 KB)

References

[1]. Tang H, et al. Author Correction: Lysyl oxidase drives tumour progression by trapping EGF receptors at the cell surface. Nat Commun. 2019 Jul 18;10(1):3151. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.2523 mL	11.2615 mL	22.5230 mL	56.3076 mL
	5 mM	0.4505 mL	2.2523 mL	4.5046 mL	11.2615 mL
	10 mM	0.2252 mL	1.1262 mL	2.2523 mL	5.6308 mL
	15 mM	0.1502 mL	0.7508 mL	1.5015 mL	3.7538 mL
	20 mM	0.1126 mL	0.5631 mL	1.1262 mL	2.8154 mL
	25 mM	0.0901 mL	0.4505 mL	0.9009 mL	2.2523 mL
	30 mM	0.0751 mL	0.3754 mL	0.7508 mL	1.8769 mL
	40 mM	0.0563 mL	0.2815 mL	0.5631 mL	1.4077 mL
	50 mM	0.0450 mL	0.2252 mL	0.4505 mL	1.1262 mL
	60 mM	0.0375 mL	0.1877 mL	0.3754 mL	0.9385 mL
	80 mM	0.0282 mL	0.1408 mL	0.2815 mL	0.7038 mL
	100 mM	0.0225 mL	0.1126 mL	0.2252 mL	0.5631 mL